Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
38.84
+0.66 (1.73%)
At close: Aug 22, 2025, 4:00 PM
38.07
-0.77 (-1.98%)
After-hours: Aug 22, 2025, 7:32 PM EDT
Xenon Pharmaceuticals Revenue
Xenon Pharmaceuticals had revenue of $7.50M in the twelve months ending June 30, 2025.
Revenue (ttm)
$7.50M
Revenue Growth
n/a
P/S Ratio
399.31
Revenue / Employee
$22,936
Employees
327
Market Cap
2.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 9.43M | -9.00M | -48.83% |
| Dec 31, 2021 | 18.44M | -13.73M | -42.68% |
| Dec 31, 2020 | 32.17M | 25.34M | 371.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
XENE News
- 11 days ago - Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release - Seeking Alpha
- 12 days ago - Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Xenon Reports Second Quarter 2025 Financial Results & Business Update - GlobeNewsWire
- 19 days ago - Xenon to Report Q2 2025 Financial Results on August 11, 2025 - GlobeNewsWire
- 22 days ago - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Xenon Joins the Russell 3000® and Russell 2000® Indexes - GlobeNewsWire
- 2 months ago - Xenon Announces Appointment of Darren Cline as Chief Commercial Officer - GlobeNewsWire
- 2 months ago - Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire